2024 established foundation for Powering Care
strategy while delivering an above-algorithm year
2025
outlook reflects continued organic growth and operating momentum as
transformation progresses
DALLAS, Jan. 28,
2025 /PRNewswire/ -- Kimberly-Clark Corporation
(NYSE: KMB) today reported fourth quarter and full year 2024
results that illustrated the strength of its innovation-led growth
model, driving volume gains, improving product mix, and generating
significant efficiencies enabling reinvestment in its brands, new
capabilities, and generating attractive returns to its
shareholders.
"2024 was a breakthrough year for Kimberly-Clark with the launch
of our transformative, multi-year Powering Care strategy and
successfully rewiring our organization into three powerhouse
segments with world-class functional support," said Kimberly-Clark
Chairman and CEO, Mike Hsu. "Our
full-year results exceeded our new long-term growth algorithm -
supported by consistent execution across the organization - and we
established a strong foundation to accelerate our strategy in 2025
and beyond."
"We delivered organic top-line growth with an upward inflection
in volume-plus-mix. This, coupled with improved productivity, has
driven strong adjusted profit growth and fueled investments to
advance our competitive advantage." Hsu continued. "We're excited
about this new chapter of Kimberly-Clark, and we look forward to
building on our momentum and enhancing value for all
stakeholders."
Quarter Highlights
- Delivered net sales of $4.9
billion, down 0.8 percent, with organic sales growth of 2.3
percent.
- Gross margin was 34.0 percent. Adjusted gross margin was 35.4
percent, up 50 basis points versus the prior year with strong
productivity gains partly offset by investments and manufacturing
cost headwinds.
- Operating profit for the quarter was $548 million, while adjusted operating profit was
$684 million up 2.1 percent versus
the prior year with higher adjusted gross margin enabling higher
investments.
- Diluted earnings per share were $1.34; adjusted earnings per share were
$1.50, down 0.7 percent versus prior
year driven primarily by lower equity income offset by higher
adjusted operating profit.
Fourth Quarter 2024 Results
Fourth quarter sales of $4.9
billion were down 0.8 percent, with organic sales up 2.3
percent, driven by the highest quarterly volume growth of the year
at 1.5 percent, a 0.6 percent increase in price from ongoing
revenue growth management programs and a 0.1 percent contribution
from favorable product mix. All segments grew volume in the
quarter. Changes in foreign currency exchange rates reduced sales
by approximately 1.7 percent and the divestiture of the
Personal Protective Equipment (PPE) business reduced sales by
approximately 1.4 percent.
Gross margin was 34.0 percent in the quarter, inclusive of
$68 million, or approximately 140
basis points, of charges related to the 2024 Transformation
Initiative. Excluding these charges, adjusted gross margin was 35.4
percent, up 50 basis points versus the prior year driven by strong
productivity savings and volume gains that were partly offset by
higher manufacturing costs and supply chain investments, as well as
unfavorable pricing net of input cost inflation due to the timing
of price and cost realization.
Fourth quarter operating profit was $548 million, inclusive
of 2024 Transformation Initiative charges and other items not
reflective of our underlying operations totaling $136 million, compared to $670 million last year. Excluding these items,
adjusted operating profit was $684
million up 2.1 percent versus the prior year including
an unfavorable impact from currency translation of 1.8 percent and
an unfavorable impact from divestitures of 1.8 percent. This
reflected the increase in adjusted gross profit dollars that was
partly offset by planned increases in marketing, research, selling
and general expenses.
Net interest expense was $53
million, 39.5 percent higher than prior year driven by lower
interest income.
Fourth quarter effective tax rate was 14.8 percent. On an
adjusted basis, the effective rate in the fourth quarter was 25.2
percent, in line with the prior year.
Net income of equity companies was $44 million compared to
$53 million last year, primarily
driven by the adverse impact of currency translation on earnings
related to Kimberly-Clark de Mexico.
Diluted EPS in the quarter were $1.34 on a reported basis, down from $1.50 the prior year due to charges related to
the company's 2024 Transformation Initiative. On an adjusted basis,
EPS decreased 0.7 percent to $1.50 as
benefits from the growth in adjusted operating profit and lower
diluted shares outstanding were offset by the reduction in income
from equity companies.
Full Year 2024 Results
2024 net sales of $20.1 billion
were 1.8 percent lower than the prior year due to negative impacts
of approximately 3.8 percent from foreign currency translation and
1.2 percent from divestitures. Organic sales grew 3.2 percent,
driven by an approximately 1.9 percent increase in price, primarily
in hyperinflationary economies, a 0.8 percent increase in volume
and a 0.4 percent benefit from favorable product mix.
2024 gross margin was 35.8 percent, inclusive of $144 million, or approximately 70 basis points,
of charges related to the 2024 Transformation
Initiative. Excluding these charges, 2024 adjusted gross
margin was 36.5 percent, a meaningful expansion of 200 basis points
versus the prior year driven by strong productivity savings,
favorable pricing net of cost inflation, volume and mix led gains
partly offset by manufacturing cost headwinds.
2024 operating profit was $3.2
billion, including $565
million of gains from the divestiture of the company's PPE
business, and $456 million of charges
related to the company's 2024 Transformation Initiative.
2024 adjusted operating profit was $3.2
billion versus $3.0 billion in
the prior year. This was an increase of 9.4 percent versus prior
year and included an unfavorable impact of 6.2 percentage points
from currency translation, primarily driven by hyperinflationary
economies. Excluding these impacts, the growth in adjusted
operating profit was driven by a combination of organic growth,
strong productivity savings, and favorable pricing net of input
cost inflation that were partly offset by supply chain related
investments and planned increases in marketing, research and
general expenses.
In 2024, diluted earnings per share were $7.55 compared to $5.21 last year. 2024 adjusted earnings per share
were $7.30 compared to $6.57 last year, an increase of 11.1 percent,
primarily reflecting the strong growth in adjusted operating
profit.
Business Segment Results
Q4 changes vs. year
ago (%)
|
|
Volume
|
|
Mix/Other
|
|
Net
Price
|
|
Divestitures
and
Business
Exits(c)
|
|
Currency
Translation
|
|
Total(a)
|
|
Organic(b)
|
Consolidated
|
|
1.5
|
|
0.1
|
|
0.6
|
|
(1.4)
|
|
(1.7)
|
|
(0.8)
|
|
2.3
|
NA
|
|
1.9
|
|
—
|
|
(0.8)
|
|
(1.6)
|
|
(0.1)
|
|
(0.5)
|
|
1.1
|
IPC
|
|
0.9
|
|
0.3
|
|
4.1
|
|
(0.1)
|
|
(6.4)
|
|
(1.3)
|
|
5.3
|
IFP
|
|
1.0
|
|
0.2
|
|
(0.5)
|
|
(2.6)
|
|
0.8
|
|
(1.2)
|
|
0.7
|
FY changes vs. year
ago (%)
|
|
Volume
|
|
Mix/Other
|
|
Net
Price
|
|
Divestitures
and
Business
Exits(c)
|
|
Currency
Translation
|
|
Total(a)
|
|
Organic(b)
|
Consolidated
|
|
0.8
|
|
0.4
|
|
1.9
|
|
(1.2)
|
|
(3.8)
|
|
(1.8)
|
|
3.2
|
NA
|
|
0.5
|
|
0.5
|
|
0.1
|
|
(0.8)
|
|
(0.1)
|
|
0.2
|
|
1.1
|
IPC
|
|
0.9
|
|
0.5
|
|
7.8
|
|
(0.1)
|
|
(12.2)
|
|
(3.1)
|
|
9.2
|
IFP
|
|
1.5
|
|
0.3
|
|
(2.0)
|
|
(4.4)
|
|
(1.2)
|
|
(5.9)
|
|
(0.2)
|
|
|
(a)
|
Total may not sum
across due to rounding.
|
(b)
|
Represents the change
in net sales excluding the impacts of currency translation and
divestitures and business exits. Organic Sales Growth is a non-GAAP
financial measure. See "Summary of Non-GAAP Financial Measures"
below for reconciliations of our GAAP to non-GAAP
measures.
|
(c)
|
Impact of the sale of
the Brazil tissue and professional business, sale of the PPE
business and other exited businesses and markets in conjunction
with the 2024 Transformation Initiative.
|
North America (NA)
North America net sales of
$2.7 billion decreased 0.5 percent in
the fourth quarter, with organic sales increasing 1.1 percent that
were primarily driven by volume growth of 1.9 percent.
FY net sales of $11.0 billion were
essentially flat versus the prior year with organic sales growing
1.1 percent driven by balanced contributions from volume and mix.
Growth was driven by Adult Care and Baby and Child Care with
innovation and strong commercial execution driving share gains
in both the fourth quarter and full year.
Fourth-quarter operating profit of $548
million decreased 10.0 percent versus the prior year
reflecting strong productivity gains that were more than offset by
a combination of a planned, double-digit increase in marketing,
greater strategic capability spending, incremental manufacturing
and distribution costs associated with temporary supply chain
disruptions, and unfavorable pricing net of cost inflation due to
the timing of price and cost realization.
Operating profit for the year increased 1.1 percent to
$2.5 billion driven by strong
productivity savings, contributions from volume and mix and
modestly favorable price net of cost inflation partly offset by
manufacturing cost headwinds, investments in advertising and
product improvement.
International Personal Care (IPC)
IPC net sales of $1.4 billion
decreased 1.3 percent in the quarter, while organic sales were up
5.3 percent reflecting price gains of 4.1 percent and a volume
increase of 0.9 percent. Pricing in the quarter was driven
primarily by hyperinflationary economies while volume growth was
driven by double-digit volume growth in China.
FY net sales of $5.7 billion
decreased 3.1 percent while organic sales grew 9.2 percent
reflecting pricing in hyperinflationary economies, volume growth
driven by double-digit volume growth in China, as well as gains from product mix
versus the prior year.
Fourth-quarter operating profit of $155
million increased 36.0 percent driven primarily by lower
impact from monetary losses from hyperinflationary economies.
Strong productivity savings and favorable pricing net of cost
inflation fueled greater investments in advertising and selling
expenses.
Operating profit for the year increased 24.5 percent to
$787 million driven by lower monetary
losses from hyperinflationary economies, favorable price net of
cost inflation and strong productivity savings partly offset by
unfavorable currency translation, manufacturing cost headwinds and
investments in advertising and product improvement.
International Family Care & Professional (IFP)
IFP net sales of $831 million
decreased 1.2 percent in the quarter, while organic sales increased
0.7 percent with volume growing 1.0 percent offset by negative
price of 0.5 percent. Volume growth was driven by growth in Family
Care in Western & Central
Europe and Australia.
FY net sales of $3.3 billion
decreased 5.9 percent primarily driven by a 4.4 percent impact from
divestitures and business exits. Organic sales were broadly flat
versus the prior year with volume growth of 1.5 percent offset by
negative price of 2.0 percent which was driven by lapping of
temporary energy related surcharges in Europe.
Fourth-quarter operating profit of $89
million increased 30.9 percent with gains from productivity
savings, volume growth and better utilization of assets that more
than offset investments in advertising and a planned increase in
research, selling and general expenses.
Operating profit for the year increased 31.4 percent to
$377 million driven primarily by
strong productivity savings during the year.
Cash Flow and Balance Sheet
Full-year cash provided by operations was $3.2 billion compared to $3.5 billion last year. 2024 capital spending was
$721 million compared to
$766 million last year. The company returned $2.6 billion to shareholders through dividends
and share repurchases. The company completed share
repurchases of 7.2 million shares at a cost of $1.0 billion in 2024. Total debt was $7.4 billion as of December 31, 2024 compared to $8.0 billion at the end of 2023.
2025 Outlook
Consistent with the Company's long term growth algorithm, it
currently expects 2025 Organic Sales Growth to outpace the weighted
average growth in the categories and countries it competes, which
are currently growing at approximately two percent. Reported Net
Sales are forecast to reflect a negative impact of approximately
300 basis points from currency translation as well as a negative
240 basis point impact from a combination of its PPE divestiture
and the exit of the company's private label diaper businesses in
the US. Adjusted Operating Profit is expected to grow at a high
single-digit rate on a constant-currency basis including a negative
320 basis point impact from a combination of its PPE divestiture
and the exit of the company's private label diaper businesses in
the US. Operating Profit growth is also expected to be negatively
impacted by approximately 300 basis points from currency
translation. Adjusted Earnings Per share are expected to grow at a
mid-to-high single-digit rate on a constant-currency basis
including a negative 320 basis point impact from a combination of
its PPE divestiture and the exit of the company's private label
diaper businesses in the US as well as a negative 100 basis point
impact from items below operating profit including an impact from
higher net interest expense, a higher effective adjusted tax rate
and lower shares outstanding, among others. Earnings Per Share are
also currently expected to be negatively impacted by approximately
350-400 basis points from currency translation, including the
impact on income from equity interests.
This outlook reflects assumptions subject to change given the
macro environment.
Supplemental Materials and Live Webcast
Supplemental materials will be available at approximately
6:30 a.m. Eastern Standard Time in
the Investor Relations section of www.kimberly-clark.com. The
company will host a live Q&A session with investors and
analysts on January 28, 2025, at
8:00 a.m. Eastern Standard Time. The
supplemental materials and Kimberly-Clark's Q&A session can be
accessed at investor.kimberly-clark.com. A replay of the
webcast will be available following the event through the same
website.
About Kimberly-Clark
Kimberly-Clark (NYSE: KMB) and its trusted brands are an
indispensable part of life for people in more than 175 countries
and territories. Fueled by ingenuity, creativity, and an
understanding of people's most essential needs, we create products
that help individuals experience more of what's important to them.
Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex,
Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus,
Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2
share positions in approximately 70 countries. We use sustainable
practices that support a healthy planet, build strong communities,
and ensure our business thrives for decades to come. We are proud
to be recognized as one of the World's Most Ethical
Companies(R) by Ethisphere for the sixth year in a
row and one of Fortune's Most Innovative Companies in America in
2024. To keep up with the latest news and to learn about the
company's more than 150-year history of innovation, visit the
Kimberly-Clark website.
Copies of Kimberly-Clark's Annual Report to Stockholders and its
proxy statements and other SEC filings, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K, are made available free of charge on the company's
website on the same day they are filed with the SEC. To view these
filings, visit the Investors section of the company's website.
Forward Looking Statements
Certain matters contained in this news release concerning the
business outlook, including raw material, energy and other input
costs, the anticipated charges and savings from the 2024
Transformation Initiative, cash flow and uses of cash, growth
initiatives, innovations, marketing and other spending, net sales,
anticipated currency rates and exchange risks, including the impact
in Argentina and Türkiye,
effective tax rate, contingencies and anticipated transactions of
Kimberly-Clark, including dividends, share repurchases and pension
contributions, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and
are based upon management's expectations and beliefs concerning
future events impacting Kimberly-Clark. There can be no assurance
that these future events will occur as anticipated or that our
results will be as estimated. Forward-looking statements speak only
as of the date they were made, and we undertake no obligation to
publicly update them.
The assumptions used as a basis for the forward-looking
statements include many estimates that, among other things, depend
on the achievement of future cost savings and projected volume
increases. In addition, many factors outside our control, including
the risk that we are not able to realize the anticipated benefits
of the 2024 Transformation Initiative (including risks related to
disruptions to our business or operations or related to any delays
in implementation), war in Ukraine
(including the related responses of consumers, customers, and
suppliers and sanctions issued by the U.S., the European Union,
Russia or other countries),
pandemics, epidemics, fluctuations in foreign currency exchange
rates, the prices and availability of our raw materials, supply
chain disruptions, disruptions in the capital and credit markets,
counterparty defaults (including customers, suppliers and financial
institutions with which we do business), failure to realize the
expected benefits or synergies from our acquisition and disposition
activity, impairment of goodwill and intangible assets and our
projections of operating results and other factors that may affect
our impairment testing, changes in customer preferences, severe
weather conditions, regional instabilities and hostilities
(including the war in Israel),
government trade or similar regulatory actions, potential
competitive pressures on selling prices for our products, energy
costs, general economic and political conditions globally and in
the markets in which we do business, as well as our ability to
maintain key customer relationships, could affect the realization
of these estimates.
The factors described under Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31,
2023, or in our other SEC filings, among others, could cause our
future results to differ from those expressed in any
forward-looking statements made by us or on our behalf. Other
factors not presently known to us or that we presently consider
immaterial could also affect our business operations and financial
results.
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF INCOME
(Millions, except per
share amounts)
|
|
|
|
|
|
Three Months
Ended
December
31
|
|
|
|
2024
|
|
2023
|
|
Change
|
Net
Sales
|
$
4,928
|
|
$
4,970
|
|
(0.8) %
|
Cost of products
sold
|
3,253
|
|
3,233
|
|
0.6 %
|
Gross
Profit
|
1,675
|
|
1,737
|
|
(3.6) %
|
Marketing, research
and general expenses
|
1,109
|
|
993
|
|
11.7 %
|
Other (income) and
expense, net
|
18
|
|
74
|
|
(75.7) %
|
Operating
Profit
|
548
|
|
670
|
|
(18.2) %
|
Nonoperating
expense
|
(16)
|
|
(18)
|
|
(11.1) %
|
Interest
income
|
11
|
|
32
|
|
(65.6) %
|
Interest
expense
|
(64)
|
|
(70)
|
|
(8.6) %
|
Income Before Income
Taxes and Equity Interests
|
479
|
|
614
|
|
(22.0) %
|
Provision for income
taxes
|
(71)
|
|
(155)
|
|
(54.2) %
|
Income Before Equity
Interests
|
408
|
|
459
|
|
(11.1) %
|
Share of net income of
equity companies
|
44
|
|
53
|
|
(17.0) %
|
Net
Income
|
452
|
|
512
|
|
(11.7) %
|
Net income
attributable to noncontrolling interests
|
(5)
|
|
(3)
|
|
66.7 %
|
Net Income
Attributable to Kimberly-Clark Corporation
|
$
447
|
|
$ 509
|
|
(12.2) %
|
|
|
|
|
|
|
Per Share
Basis
|
|
|
|
|
|
Net Income
Attributable to Kimberly-Clark Corporation
|
|
|
|
|
|
Basic
|
$
1.34
|
|
$ 1.51
|
|
(11.3) %
|
Diluted
|
$
1.34
|
|
$ 1.50
|
|
(10.7) %
|
|
|
|
|
|
|
Cash Dividends
Declared
|
$
1.22
|
|
$ 1.18
|
|
3.4 %
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
Outstanding
|
December
31
|
|
|
|
2024
|
|
2023
|
|
|
Outstanding shares as
of
|
331.8
|
|
337.0
|
|
|
Average diluted shares
for three months ended
|
334.4
|
|
339.0
|
|
|
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF INCOME
(Millions, except per
share amounts)
|
|
|
|
|
|
Twelve Months
Ended
December
31
|
|
|
|
2024
|
|
2023
|
|
Change
|
Net
Sales
|
$
20,058
|
|
$
20,431
|
|
(1.8) %
|
Cost of products
sold
|
12,878
|
|
13,399
|
|
(3.9) %
|
Gross
Profit
|
7,180
|
|
7,032
|
|
2.1 %
|
Marketing, research
and general expenses
|
4,311
|
|
3,961
|
|
8.8 %
|
Impairment of
intangible assets
|
97
|
|
658
|
|
(85.3) %
|
Other (income) and
expense, net
|
(438)
|
|
69
|
|
N.M.
|
Operating
Profit
|
3,210
|
|
2,344
|
|
36.9 %
|
Nonoperating
expense
|
(61)
|
|
(96)
|
|
(36.5) %
|
Interest
income
|
48
|
|
66
|
|
(27.3) %
|
Interest
expense
|
(270)
|
|
(293)
|
|
(7.8) %
|
Income Before Income
Taxes and Equity Interests
|
2,927
|
|
2,021
|
|
44.8 %
|
Provision for income
taxes
|
(565)
|
|
(453)
|
|
24.7 %
|
Income Before Equity
Interests
|
2,362
|
|
1,568
|
|
50.6 %
|
Share of net income of
equity companies
|
216
|
|
196
|
|
10.2 %
|
Net
Income
|
2,578
|
|
1,764
|
|
46.1 %
|
Net income
attributable to noncontrolling interests
|
(33)
|
|
—
|
|
N.M.
|
Net Income
Attributable to Kimberly-Clark Corporation
|
$
2,545
|
|
$
1,764
|
|
44.3 %
|
|
|
|
|
|
|
Per Share
Basis
|
|
|
|
|
|
Net Income
Attributable to Kimberly-Clark Corporation
|
|
|
|
|
|
Basic
|
$
7.58
|
|
$ 5.22
|
|
45.2 %
|
Diluted
|
$
7.55
|
|
$ 5.21
|
|
44.9 %
|
|
|
|
|
|
|
Cash Dividends
Declared
|
$
4.88
|
|
$ 4.72
|
|
3.4 %
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
Outstanding
|
December
31
|
|
|
|
2024
|
|
2023
|
|
|
Average diluted shares
for twelve months ended
|
337.0
|
|
338.8
|
|
|
N.M. - Not
Meaningful
|
2024 Data is
Unaudited
|
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED BALANCE
SHEETS
(Millions)
|
|
|
|
December
31
|
|
2024
|
|
2023
|
ASSETS
|
|
|
|
Current
Assets
|
|
|
|
Cash and cash
equivalents
|
$
1,021
|
|
$
1,093
|
Accounts receivable,
net
|
2,009
|
|
2,135
|
Inventories
|
1,822
|
|
1,955
|
Other current
assets
|
728
|
|
520
|
Total Current
Assets
|
5,580
|
|
5,703
|
Property, Plant and
Equipment, Net
|
7,513
|
|
7,913
|
Investments in
Equity Companies
|
314
|
|
306
|
Goodwill
|
1,964
|
|
2,085
|
Other Intangible
Assets, Net
|
87
|
|
197
|
Other
Assets
|
1,088
|
|
1,140
|
TOTAL
ASSETS
|
$
16,546
|
|
$
17,344
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
Current
Liabilities
|
|
|
|
Debt payable within
one year
|
$
568
|
|
$
567
|
Trade accounts
payable
|
3,715
|
|
3,653
|
Accrued expenses and
other current liabilities
|
2,319
|
|
2,316
|
Dividends
payable
|
402
|
|
394
|
Total Current
Liabilities
|
7,004
|
|
6,930
|
Long-Term
Debt
|
6,875
|
|
7,417
|
Noncurrent Employee
Benefits
|
643
|
|
669
|
Deferred Income
Taxes
|
326
|
|
374
|
Other
Liabilities
|
686
|
|
860
|
Redeemable Preferred
Securities of Subsidiaries
|
37
|
|
26
|
Stockholders'
Equity
|
|
|
|
Kimberly-Clark
Corporation
|
840
|
|
915
|
Noncontrolling
Interests
|
135
|
|
153
|
Total Stockholders'
Equity
|
975
|
|
1,068
|
TOTAL LIABILITIES
AND STOCKHOLDERS' EQUITY
|
$
16,546
|
|
$
17,344
|
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF CASH FLOWS
(Millions)
|
|
|
|
|
|
Twelve Months
Ended
December
31
|
|
|
2024
|
|
2023
|
Operating
Activities
|
|
|
|
|
Net income
|
|
$
2,578
|
|
$
1,764
|
Depreciation and
amortization
|
|
781
|
|
753
|
Asset
impairments
|
|
114
|
|
676
|
Stock-based
compensation
|
|
131
|
|
169
|
Deferred income
taxes
|
|
(38)
|
|
(322)
|
Net (gains) losses on
asset and business dispositions
|
|
(448)
|
|
(75)
|
Equity companies'
earnings (in excess of) less than dividends paid
|
|
(62)
|
|
(59)
|
Operating working
capital
|
|
178
|
|
582
|
Postretirement
benefits
|
|
3
|
|
24
|
Other
|
|
(3)
|
|
30
|
Cash Provided by
Operations
|
|
3,234
|
|
3,542
|
Investing
Activities
|
|
|
|
|
Capital
spending
|
|
(721)
|
|
(766)
|
Proceeds from asset
and business dispositions
|
|
651
|
|
245
|
Investments in time
deposits
|
|
(605)
|
|
(720)
|
Maturities of time
deposits
|
|
562
|
|
815
|
Other
|
|
13
|
|
8
|
Cash Used for
Investing
|
|
(100)
|
|
(418)
|
Financing
Activities
|
|
|
|
|
Cash dividends
paid
|
|
(1,628)
|
|
(1,588)
|
Change in short-term
debt
|
|
1
|
|
(371)
|
Debt
proceeds
|
|
—
|
|
363
|
Debt
repayments
|
|
(554)
|
|
(475)
|
Proceeds from exercise
of stock options
|
|
136
|
|
97
|
Acquisitions of common
stock for the treasury
|
|
(1,000)
|
|
(225)
|
Cash paid for
redemption of common securities of Thinx
|
|
—
|
|
(95)
|
Cash dividends paid to
noncontrolling interests
|
|
(35)
|
|
(35)
|
Other
|
|
(86)
|
|
(45)
|
Cash Used for
Financing
|
|
(3,166)
|
|
(2,374)
|
Effect of Exchange
Rate Changes on Cash and Cash Equivalents
|
|
(40)
|
|
(84)
|
Change in Cash and
Cash Equivalents
|
|
(72)
|
|
666
|
Cash and Cash
Equivalents - Beginning of Period
|
|
1,093
|
|
427
|
Cash and Cash
Equivalents - End of Period
|
|
$
1,021
|
|
$
1,093
|
KIMBERLY-CLARK
CORPORATION
BUSINESS SEGMENT
RESULTS
(Millions)
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended December 31
|
|
|
|
Twelve Months
Ended December 31
|
|
|
|
|
2024
|
|
2023
|
|
Change
|
|
2024
|
|
2023
|
|
Change
|
Net
Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
NA
|
|
$
2,722
|
|
$
2,736
|
|
(0.5) %
|
|
$
11,008
|
|
$ 10,988
|
|
0.2 %
|
IPC
|
|
1,375
|
|
1,393
|
|
(1.3) %
|
|
5,715
|
|
5,899
|
|
(3.1) %
|
IFP
|
|
831
|
|
841
|
|
(1.2) %
|
|
3,335
|
|
3,544
|
|
(5.9) %
|
Total Net
Sales
|
|
$
4,928
|
|
$
4,970
|
|
(0.8) %
|
|
$
20,058
|
|
$ 20,431
|
|
(1.8) %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
NA
|
|
$ 548
|
|
$ 609
|
|
(10.0) %
|
|
$
2,534
|
|
$
2,507
|
|
1.1 %
|
IPC
|
|
155
|
|
114
|
|
36.0 %
|
|
787
|
|
632
|
|
24.5 %
|
IFP
|
|
89
|
|
68
|
|
30.9 %
|
|
377
|
|
287
|
|
31.4 %
|
Segment Operating
Profit(a)
|
|
792
|
|
791
|
|
0.1 %
|
|
3,698
|
|
3,426
|
|
7.9 %
|
Corporate &
Other
|
|
(244)
|
|
(121)
|
|
101.7 %
|
|
(488)
|
|
(1,082)
|
|
(54.9) %
|
Total Operating
Profit
|
|
$ 548
|
|
$ 670
|
|
(18.2) %
|
|
$
3,210
|
|
$
2,344
|
|
36.9 %
|
|
|
(a)
|
Total Segment Operating
Profit is a non-GAAP financial measure as it excludes certain
unallocated general corporate expenses and income and expense not
associated with the ongoing operations of the segments. Refer to
the Non-GAAP Financial Measures section below for further
discussion of how we utilize non-GAAP financial measures. As shown
above, we have included a reconciliation to Total Operating Profit,
as determined in accordance with GAAP.
|
SUMMARY OF NON-GAAP FINANCIAL MEASURES
The following provides the reconciliation of the non-GAAP
financial measures provided in this news release to the most
closely related GAAP measure. These measures include: Organic Sales
Growth, Adjusted Gross Profit, Adjusted Operating Profit, Adjusted
Earnings per Share, and Adjusted Effective Tax Rate.
- Organic Sales Growth is defined as the change in consolidated
Net Sales, as determined in accordance with U.S. GAAP, excluding
the impacts of currency translation and divestitures and business
exits.
- Adjusted Gross and Operating Profit, Adjusted Earnings per
Share, and Adjusted Effective Tax Rate are defined as consolidated
Gross Profit, Operating Profit, Diluted Earnings per Share, and
Effective Tax Rate, respectively, as determined in accordance with
U.S. GAAP, excluding the impacts of certain items that management
believes do not reflect our underlying operations, and which are
discussed in further detail below.
The income tax effect of these non-GAAP items on the Company's
Adjusted Earnings per Share is calculated based upon the tax laws
and statutory income tax rates applicable in the tax
jurisdiction(s) of the underlying non-GAAP adjustment. The impact
of these non-GAAP items on the Company's effective tax rate
represents the difference in the effective tax rate calculated with
and without the non-GAAP adjustment on Income Before Income Taxes
and Equity Interests and Provision for income taxes.
We use these non-GAAP financial measures to assist in comparing
our performance on a consistent basis for purposes of business
decision making by removing the impact of certain items that we do
not believe reflect our underlying and ongoing operations. We
believe that presenting these non-GAAP financial measures is useful
to investors because it (i) provides investors with meaningful
supplemental information regarding financial performance by
excluding certain items, (ii) permits investors to view performance
using the same tools that management uses to budget, make operating
and strategic decisions, and evaluate historical performance, and
(iii) otherwise provides supplemental information that may be
useful to investors in evaluating our results. We believe that the
presentation of these non-GAAP financial measures, when considered
together with the corresponding U.S. GAAP financial measures and
the reconciliation to those measures, provides investors with
additional understanding of the factors and trends affecting our
business than could be obtained absent these disclosures.
These non-GAAP financial measures are not meant to be considered
in isolation or as a substitute for the comparable GAAP measures,
and they should be read only in conjunction with our consolidated
financial statements prepared in accordance with GAAP. There are
limitations to these non-GAAP financial measures because they are
not prepared in accordance with GAAP and may not be comparable to
similarly titled measures of other companies due to potential
differences in methods of calculation and items being excluded. We
compensate for these limitations by using these non-GAAP financial
measures as a supplement to the GAAP measures and by providing
reconciliations of the non-GAAP and comparable GAAP financial
measures. Certain non-GAAP financial measures referenced in this
news release are presented on a forward-looking basis.
Kimberly-Clark does not provide a reconciliation of these
forward-looking non-GAAP financial measures to the most directly
comparable GAAP financial measures on a forward-looking basis
because it is unable to predict certain adjustment items without
unreasonable effort. Please note that these items could be material
to Kimberly-Clark's results calculated in accordance with GAAP.
The non-GAAP financial measures exclude the following items for
the relevant time periods:
- 2024 Transformation Initiative - We initiated this
transformation to create a more agile and focused operating
structure that will accelerate our proprietary pipeline of
innovation in right-to-win spaces and improve our growth
trajectory, profitability, and returns on investment. Results in
2024 include charges related to this program. See Item 8, Note 2 to
the consolidated financial statements for details.
- Sale of PPE Business - In 2024, we recognized a gain
related to the sale of our PPE business. See Item 8, Note 3 to
the consolidated financial statements for details.
- Impairment of Intangible Assets - In 2024 and 2023, we
recognized charges related to the impairment of certain intangible
assets related to Softex and Thinx. See Item 8, Note 4 to the
consolidated financial statements for details.
- Legal Expense - In 2024, we incurred certain costs related to
litigation and regulatory matters for a previously exited
business.
- Softex Tax Reserve Release - In 2024 we released a reserve for
an uncertain tax position related to the prior year impairment of
certain Softex intangible assets.
- Sale of Brazil Tissue and Professional Business - In 2023, we
recognized a net benefit related to the sale of our Neve tissue
brand and related consumer and professional tissue assets. See Item
8, Note 3 to the consolidated financial statements for
details.
- Pension Settlements - In 2023, pension settlement charges were
recognized related to lump-sum distributions from pension plan
assets exceeding the total of annual service and interest costs
resulting in a recognition of deferred actuarial losses.
The following tables provide a reconciliation of Organic Sales
Growth:
|
Three Months Ended
December 31, 2024
|
|
Percent change vs.
the prior year period
|
|
NA
|
|
IPC
|
|
IFP
|
|
Consolidated
|
Net Sales
Growth
|
(0.5)
|
|
(1.3)
|
|
(1.2)
|
|
(0.8)
|
Currency
Translation
|
0.1
|
|
6.4
|
|
(0.8)
|
|
1.7
|
Divestitures and
Business Exits
|
1.5
|
|
0.2
|
|
2.7
|
|
1.4
|
Organic Sales
Growth
|
1.1
|
|
5.3
|
|
0.7
|
|
2.3
|
|
Year Ended December
31, 2024
|
|
Percent change vs.
the prior year period
|
|
NA
|
|
IPC
|
|
IFP
|
|
Consolidated
|
Net Sales
Growth
|
0.2
|
|
(3.1)
|
|
(5.9)
|
|
(1.8)
|
Currency
Translation
|
0.1
|
|
12.2
|
|
1.2
|
|
3.8
|
Divestitures and
Business Exits
|
0.8
|
|
0.1
|
|
4.5
|
|
1.2
|
Organic Sales
Growth
|
1.1
|
|
9.2
|
|
(0.2)
|
|
3.2
|
The following table provides a reconciliation of Adjusted Gross
Profit:
|
Three Months Ended
December 31
|
|
Year Ended December
31
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Gross
Profit
|
$
1,675
|
|
$
1,737
|
|
$
7,180
|
|
$
7,032
|
2024 Transformation
Initiative
|
68
|
|
—
|
|
144
|
|
—
|
Sale of Brazil Tissue
and Professional Business
|
—
|
|
—
|
|
—
|
|
15
|
Adjusted Gross
Profit
|
$
1,743
|
|
$
1,737
|
|
$
7,324
|
|
$
7,047
|
The following table provides a reconciliation of Adjusted
Operating Profit:
|
Three Months Ended
December 31
|
|
Year Ended December
31
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Operating
Profit
|
$
548
|
|
$
670
|
|
$
3,210
|
|
$
2,344
|
2024 Transformation
Initiative
|
97
|
|
—
|
|
456
|
|
—
|
Sale of PPE
Business
|
—
|
|
—
|
|
(565)
|
|
—
|
Impairment of
Intangible Assets
|
—
|
|
—
|
|
97
|
|
658
|
Legal
Expense
|
39
|
|
—
|
|
39
|
|
—
|
Sale of Brazil Tissue
and Professional Business
|
—
|
|
—
|
|
—
|
|
(44)
|
Adjusted Operating
Profit
|
$
684
|
|
$
670
|
|
$
3,237
|
|
$
2,958
|
The following table provides a reconciliation of Adjusted
Earnings per Share:
|
Three Months Ended
December 31
|
|
Year Ended December
31
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Diluted Earnings per
Share
|
$
1.34
|
|
$
1.50
|
|
$
7.55
|
|
$
5.21
|
2024 Transformation
Initiative
|
0.25
|
|
—
|
|
1.01
|
|
—
|
Sale of PPE
Business
|
—
|
|
—
|
|
(1.34)
|
|
—
|
Impairment of
Intangible Assets
|
—
|
|
—
|
|
0.17
|
|
1.36
|
Legal
Expense
|
0.11
|
|
—
|
|
0.11
|
|
—
|
Softex Tax Reserve
Release
|
(0.20)
|
|
—
|
|
(0.20)
|
|
—
|
Sale of Brazil Tissue
and Professional Business
|
—
|
|
—
|
|
—
|
|
(0.08)
|
Pension
Settlements
|
—
|
|
0.01
|
|
—
|
|
0.08
|
Adjusted Earnings
per Share(a)
|
$
1.50
|
|
$
1.51
|
|
$
7.30
|
|
$
6.57
|
|
|
(a)
|
The non-GAAP
adjustments included above are presented net of tax. The income tax
effect of these non-GAAP items is calculated based upon the tax
laws and statutory income tax rates applicable in the tax
jurisdiction(s) of the underlying non-GAAP adjustment. Refer to the
Adjusted Effective Tax Rate reconciliation below for the tax effect
of these adjustments on the Company's reported Provision for income
taxes.
|
The following tables provide a reconciliation of the Adjusted
Effective Tax Rate:
|
Three Months Ended
December 31
|
|
2024
|
|
2023
|
|
Income Before
Income Taxes
and Equity
Interests
|
|
Provision for
Income Taxes
|
|
Income Before
Income Taxes
and Equity
Interests
|
|
Provision for
Income Taxes
|
As
Reported
|
$
479
|
|
$
(71)
|
|
$
614
|
|
$
(155)
|
2024 Transformation
Initiative
|
98
|
|
(16)
|
|
—
|
|
—
|
Legal
Expense
|
39
|
|
(1)
|
|
—
|
|
—
|
Softex Tax Reserve
Release
|
—
|
|
(67)
|
|
—
|
|
—
|
Pension
Settlements
|
—
|
|
—
|
|
4
|
|
(1)
|
As
Adjusted
|
$
616
|
|
$
(155)
|
|
$
618
|
|
$
(156)
|
|
|
|
|
|
|
|
|
Effective Tax
Rate
|
|
|
|
|
|
|
|
As Reported
|
|
|
14.8 %
|
|
|
|
25.2 %
|
As Adjusted
|
|
|
25.2 %
|
|
|
|
25.2 %
|
|
Year Ended December
31
|
|
2024
|
|
2023
|
|
Income Before
Income Taxes
and Equity
Interests
|
|
Provision for
Income Taxes
|
|
Income Before
Income Taxes
and Equity
Interests
|
|
Provision for
Income Taxes
|
As
Reported
|
$
2,927
|
|
$
(565)
|
|
$
2,021
|
|
$
(453)
|
2024 Transformation
Initiative
|
457
|
|
(118)
|
|
—
|
|
—
|
Sale of PPE
Business
|
(565)
|
|
112
|
|
—
|
|
—
|
Impairment of
Intangible Assets
|
97
|
|
(40)
|
|
658
|
|
(175)
|
Legal
Expense
|
39
|
|
(1)
|
|
—
|
|
—
|
Softex Tax Reserve
Release
|
—
|
|
(67)
|
|
—
|
|
—
|
Sale of Brazil Tissue
and Professional Business
|
—
|
|
—
|
|
(44)
|
|
18
|
Pension
Settlements
|
—
|
|
—
|
|
35
|
|
(9)
|
As
Adjusted
|
$
2,955
|
|
$
(679)
|
|
$
2,670
|
|
$
(619)
|
|
|
|
|
|
|
|
|
Effective Tax
Rate
|
|
|
|
|
|
|
|
As Reported
|
|
|
19.3 %
|
|
|
|
22.4 %
|
As Adjusted
|
|
|
23.0 %
|
|
|
|
23.2 %
|
[KMB-F]
Logo
- https://mma.prnewswire.com/media/648588/Kimberly_Clark_v1_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/kimberly-clark-delivers-solid-results-in-first-year-of-transformation-302361465.html
SOURCE Kimberly-Clark Corporation